California Bill to Decriminalize Psychedelics Put on Pause
Senator Scott Wiener’s Senate Bill 519, which would effectively decriminalize psychedelics in California, has been put on pause following his decision to pull the bill yesterday.
The bill will be reintroduced next year, according to Wiener, who explained that “over the next year [a] coalition of veterans, parents, healthcare professionals and others will continue to work hard to earn the support of Assembleymembers.”
Read more on Senator Scott Wiener’s website.
“FDA’s kratom ban would harm the public and damage the agency’s credibility”
The FDA appears poised to impose a ban on kratom, despite outcry from a diverse cohort with myriad concerns. Many worry about the implications on the opioid crisis, while others are convinced that a ban would make promising research into the plant, and its primary alkaloid mitragynine, much more difficult.
“If the FDA secures a global kratom ban, countless people could die by suicide and unintentional overdose. Many Americans say kratom curbs cravings for opioids, which are frequently obtained on the illicit market and are often laced with synthetic opioids like fentanyl. According to the CDC, synthetic opioids are “the main driver of drug overdose deaths,” responsible for nearly three-quarters of opioid-related overdoses. A ban would criminalize people who use kratom, eliminate legitimate sources of the plant, and cause many users to resort to using more harmful substances.”
As aforementioned, any form of prohibition would likely make research into these plants and their alkaloids much more difficult. As a reminder, atai has in-licensed issued and pending patents from Columbia University on deuterated mitragynine, which it is seeking to develop as a treatment for opioid disorder via its Kures program.
Read the full story, penned by Mason Marks – Senior Fellow at Harvard’s Petrie-Flom Center and Project Lead of the Project on Psychedelics Law and Regulation – over at STAT.
MIT Technology Review: An MDMA trial participant tells his story
In this piece for MIT Technology Review, a participant in an MDMA trial describes his “life-changing” experience with the psychoactive drug.
Insight Conference: September 2021
Our friends at the MIND Foundation in Berlin are hosting their second bi-annual INSIGHT conference on September 9-12.
INSIGHT 2021 will focus on integrating psychedelic states into basic research, therapies, and human development. Attendees come from all over the world to engage with leading experts from a variety of disciplines and discuss the current state of psychedelic research and its emerging future.
Learn more, and secure your virtual attendance tickets, via the Insight 2021 website (use the code PSILOALPHA10 to get 10% off tickets).